Tusk Therapeutics
Tusk Therapeutics is a privately held UK biotech founded in 2014 and headquartered in Stevenage, focused on discovering and developing therapeutic antibodies that harness the immune system to treat cancer. It operates as a small, discovery-stage immuno-oncology company.
- Company typePrivate
- Founded2014
- HeadquartersStevenage, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Tusk Therapeutics does
Tusk Therapeutics is a privately held UK biotechnology company founded in 2014 and headquartered in Stevenage, focused on the discovery and development of therapeutic antibodies that harness the immune system for the treatment of cancer. The company operates within the immuno-oncology segment of the antibody therapeutics market, targeting immune system mechanisms as a modality for oncology drug development. With a headcount in the 11-50 range, Tusk is structured as a small, discovery-stage biotech rather than a commercial-stage biopharma.
The company's recorded funding history consists of a single non-dilutive grant of approximately $3,289,370 from Innovate UK in November 2017. No venture capital rounds, strategic investments, licensing transactions, partnerships, or acquisitions are recorded in the input data, and no product pipeline, clinical-stage assets, antibody targets, or platform technology details are disclosed beyond the categorical positioning. The input data set is dominated by Roche corporate material that does not pertain to Tusk Therapeutics and should be treated as scraping noise rather than company-specific information.
Tusk Therapeutics' business model, consistent with early-stage antibody discovery biotechs, would be expected to rely on grant funding, partnership milestones, and potential licensing or acquisition outcomes rather than recurring product revenue. No commercial products, pricing models, customer logos, distribution channels, or partnership economics are disclosed, and the company description is therefore limited to its stated mission and the limited firmographic record available.
Tusk Therapeutics firmographics
Firmographics- Name
- Tusk Therapeutics
- Website
- https://tusktherapeutics.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Tusk Therapeutics is a privately held UK biotech founded in 2014 and headquartered in Stevenage, focused on discovering and developing therapeutic antibodies that harness the immune system to treat cancer. It operates as a small, discovery-stage immuno-oncology company.
- Ownership category
- akta.pro rank
Tusk Therapeutics industry classification
Industry- Product category
- Immuno-Oncology Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)
- akta.pro secondary industries
- Immunology & Inflammation Pharmaceuticals (HLAIAAAD), Recombinant Protein Therapeutics (enzymes, hormones, growth factors) (HLAAAAAB)
Keywords
Where Tusk Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Stevenage
- HQ country
- United Kingdom
- HQ region
- Europe
Markets served
Tusk Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations
Tusk Therapeutics product offering
Product offeringCore offering
Tusk Therapeutics discovers and develops unique therapeutic antibodies that harness the immune system for the treatment of cancer. The company operates as an early-stage biopharmaceutical R&D firm working on immuno-oncology antibody candidates, based in Stevenage, United Kingdom. Its offerings are pre-commercial and targeted at advancing novel cancer immunotherapies through discovery and development.
Differentiator
Problem solved
Functional benefit
Products and services
- Immuno-oncology therapeutic antibody pipeline A pipeline of therapeutic antibody candidates being discovered and developed by Tusk Therapeutics to harness the immune system for the treatment of cancer; intended for eventual licensing, partnership, or further development by pharmaceutical companies.
Companies that use Tusk Therapeutics
Customer profileIdeal customer profiles1 record
Tusk Therapeutics technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Tusk Therapeutics partnerships and signals
Strategic signalRecent moves2 records
Expansion highlights1 record
Tusk Therapeutics competitors and assessment
Company assessmentDirect peers
- F-star Therapeutics: European-headquartered biotechnology company developing bispecific antibody therapeutics for cancer, with a closely aligned discovery-stage immuno-oncology focus and similar antibody-engineering approach.
- MacroGenics: Clinical-stage biopharmaceutical company focused on discovering and developing antibody-based therapeutics for cancer, sharing the same core modality and oncology focus as Tusk.
- Innate Pharma: European-headquartered clinical-stage immuno-oncology company developing antibody-based therapeutics that leverage the immune system against cancer, broadly aligned with Tusk's therapeutic strategy.
- CytomX Therapeutics: Clinical-stage oncology company developing antibody therapeutics using a proprietary Probody platform to target cancer specifically, with a comparable antibody-engineering discovery focus.
- Surface Oncology: Clinical-stage immuno-oncology company developing antibody therapeutics that target the tumour microenvironment, sharing Tusk's focus on immune-modulating antibodies for cancer treatment.
- Crescendo Biologics: UK-based clinical-stage company engineering T cell engaging bispecific antibodies for cancer, with a comparable antibody-discovery platform approach and a similar Stevenage-area UK biotech profile.
Broad incumbents
- Compugen: Clinical-stage cancer immunotherapy company using computational platforms to discover novel immuno-oncology targets and antibody drug candidates, with a broader product pipeline and a more capitalised position than Tusk.
Emerging players
- Werewolf Therapeutics: Clinical-stage oncology company developing novel immunotherapies, with a similar emerging-stage profile and a focus on immune-engaging therapeutic approaches for cancer.
- Bolt Biotherapeutics: Clinical-stage biotechnology company developing immune-stimulating antibody conjugates for cancer, sharing Tusk's focus on harnessing the immune system via antibody-based approaches.
- Inhibrx: Clinical-stage biotechnology company developing novel antibody-based therapeutics for cancer and other diseases, with a comparable antibody-discovery and development focus.
Market position
Strengths3 records
Weaknesses3 records
Competitive moat2 records
Key risks4 records
Key highlights4 records
Customer concentration
Tusk Therapeutics social profiles
Digital presenceTusk Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Tusk Therapeutics leadership team
Management profileNumber of profiles
Tusk Therapeutics funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Tusk Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Tusk Therapeutics
What does Tusk Therapeutics do?
Tusk Therapeutics discovers and develops unique therapeutic antibodies that harness the immune system for the treatment of cancer. The company operates as an early-stage biopharmaceutical R&D firm working on immuno-oncology antibody candidates, based in Stevenage, United Kingdom. Its offerings are pre-commercial and targeted at advancing novel cancer immunotherapies through discovery and development.
When was Tusk Therapeutics founded?
Tusk Therapeutics was founded in 2014. It employs 11 to 50 people.
Where is Tusk Therapeutics based?
Tusk Therapeutics is headquartered in Stevenage, United Kingdom, in the Europe region.
Who are Tusk Therapeutics's main competitors?
Direct peers on record are F-star Therapeutics, MacroGenics, Innate Pharma, CytomX Therapeutics, Surface Oncology and Crescendo Biologics. Compugen is listed as a broad incumbent. Emerging players are Werewolf Therapeutics, Bolt Biotherapeutics and Inhibrx.
Does Tusk Therapeutics have an API?
No public API is recorded for Tusk Therapeutics.
What industry is Tusk Therapeutics in?
Tusk Therapeutics's product category is Immuno-Oncology Therapeutics. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering), with a secondary code of HLAIAAAD, Immunology & Inflammation Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2836.